Formycon AG/€FYB
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Formycon AG
Formycon AG is a biotechnology company based in Planegg, Germany, specializing in the development of biosimilar products. The company focuses primarily on creating biosimilar versions of top-selling biopharmaceuticals, addressing fields such as ophthalmology and immunology. Known for its significant expertise in protein and biopharmaceutical development, Formycon leverages its proprietary technical platform to advance its biosimilar pipeline. The company's strategic positioning includes partnerships with other pharmaceutical firms to co-develop and commercialize its biosimilar candidates. Formycon's competitive strength lies in its robust development capabilities and focus on high-growth therapeutic areas.
Ticker
€FYB
Sector
Primary listing
XETRA
Employees
245
Headquarters
Website
Formycon AG Metrics
BasicAdvanced
€341M
-
-€9.60
0.55
-
Price and volume
Market cap
€341M
Beta
0.55
52-week high
€64.40
52-week low
€19.06
Average daily volume
14K
Financial strength
Current ratio
1.541
Quick ratio
1.036
Long term debt to equity
2.121
Total debt to equity
2.499
Interest coverage (TTM)
-35.18%
Profitability
EBITDA (TTM)
113.228
Gross margin (TTM)
-0.99%
Net profit margin (TTM)
-327.88%
Operating margin (TTM)
-71.13%
Effective tax rate (TTM)
11.32%
Revenue per employee (TTM)
€210,000
Management effectiveness
Return on assets (TTM)
-2.72%
Return on equity (TTM)
-34.48%
Valuation
Price to revenue (TTM)
6.686
Price to book
0.83
Price to tangible book (TTM)
-7.13
Price to free cash flow (TTM)
-15.521
Free cash flow yield (TTM)
-6.44%
Free cash flow per share (TTM)
-1.261
Growth
Revenue change (TTM)
-14.84%
Earnings per share change (TTM)
-350.93%
3-year revenue growth (CAGR)
14.87%
10-year revenue growth (CAGR)
9.05%
3-year earnings per share growth (CAGR)
13.47%
Bulls say / Bears say
Regulatory tailwinds boost pipeline economics: the FDA’s plan to streamline biosimilar approvals by reducing clinical trial requirements is expected to accelerate development timelines and lower costs, directly benefiting Formycon’s advanced programs (Reuters turn11news13).
Interchangeability designation drives market access: the FDA granted Otulfi® (FYB202) interchangeable status in May 2025, enabling pharmacy-level substitution in the U.S. and likely enhancing uptake and payer coverage (Investing.com turn13search0).
Strengthened liquidity via bond financing: an oversubscribed €70 million corporate bond issued in July 2025 bolstered working capital and secures funding for late-stage development and commercialization activities (Formycon H1 Press Release turn6view0).
Significant revenue volatility: H1 2025 revenues fell to €9.0 million from €26.9 million a year earlier, reflecting a project transition phase and illustrating dependency on milestone payments and development service fees for cash flow (Formycon H1 Press Release turn6view0).
Continued unprofitability: Adjusted EBITDA for H1 2025 was €-19.2 million, and full-year 2025 guidance remains an EBITDA loss between €-20.0 million and €-10.0 million, highlighting ongoing cash burn ahead of expected profitability in 2026 or later (Formycon H1 Press Release turn6view0).
Dependence on legacy biosimilar: FYB201 revenues dropped to €0.6 million in Q1 2025 from €1.9 million in Q1 2024 after a U.S. commercialization pause, underscoring reliance on at-equity contributions from Bioeq AG and exposing revenue concentration risk (Formycon Q1 Press Release turn5view0).
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Formycon AG stock?
Formycon AG (FYB) has a market cap of €341M as of November 09, 2025.
What is the P/E ratio for Formycon AG stock?
The price to earnings (P/E) ratio for Formycon AG (FYB) stock is 0 as of November 09, 2025.
Does Formycon AG stock pay dividends?
No, Formycon AG (FYB) stock does not pay dividends to its shareholders as of November 09, 2025.
When is the next Formycon AG dividend payment date?
Formycon AG (FYB) stock does not pay dividends to its shareholders.
What is the beta indicator for Formycon AG?
Formycon AG (FYB) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.